Financial Data and Key Metrics Changes - Total worldwide revenue for Q3 2025 was 1.3 million, compared to a loss of 31.3 million, a 22.2% increase year-over-year [28] - Mechanical Thrombectomy revenue, including AlphaVac and AngioVac, grew 46.7% year-over-year [30] - AlphaVac revenue increased by 161.4% year-over-year, reaching 6.8 million in revenue, representing a 23.1% growth [30] Market Data and Key Metrics Changes - MedTech platforms comprised 44% of total revenue, up from 39% a year ago [28] - Auryon platform contributed 6.3 million, an increase of 5.3% [31] Company Strategy and Development Direction - The company is focused on driving profitable growth in high-margin MedTech markets [10] - Plans to leverage the momentum built in the U.S. market for Auryon and expand internationally following CE marking [48] - Continued investment in clinical data and product enhancements to support long-term adoption of technologies [49] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving cash flow positivity for the full fiscal year 2026 [44] - The company is monitoring the macro environment and potential tariffs but does not expect a material impact on business [34] - Increased guidance for fiscal 2025 includes revenue expectations of 288 million, reflecting growth of 5.3% to 6.4% [45] Other Important Information - The company has secured a revolving line of credit agreement with J.P. Morgan for 25 million [41] - R&D expenses were 6.9 million, or 9.6% of sales, down from 6.8 million revenue for AngioVac a good new base for the business going forward? - Management believes that $6.8 million is a solid base for AngioVac, expecting it to continue as a growth platform [54][56] Question: Can you provide details on NanoKnife's revenue and marketing efforts? - Management noted that prostate treatments have become the leading application for NanoKnife, with increasing monthly treatment rates [62] Question: What is the update on the AMBITION study and its significance? - The AMBITION study is expected to begin enrollment soon, aiming to demonstrate Auryon's effectiveness below the knee [85][88]
AngioDynamics(ANGO) - 2025 Q3 - Earnings Call Transcript